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Objectives: This study aims to provide the first estimates of the costs and effects of the
large scale introduction of autologous transfusion technologies into the United Kingdom
National Health Service.
Methods: A model was constructed to allow disparate data sources to be combined to
produce estimates of the scale, costs, and effects of introducing four interventions. The
interventions considered were preparing patients for surgery (PPS) clinics, preoperative
autologous donation (PAD), intraoperative cell salvage (ICS), and postoperative cell
salvage (PoCS).
Results: The key determinants of cost per operation are the anticipated level of
reductions in blood use, the mean level of blood use, mean length of stay, and the cost of
the technology. The results show the potential for considerable reductions in blood use.
The greatest reductions are anticipated to be through the use of PPS and ICS. Vascular
surgery, transplant surgery, and cardiothoracic surgery appear to be the specialties that
will benefit most from the technologies.
Conclusions: Several simplifications were used in the production of these estimates;
consequently, caution should be used in their interpretation and use. Despite the
drawbacks in the methods used in the study, the model shows the scale of the issue, the
importance of gathering better data, and the form that data must take. Such preliminary
modeling exercises are essential for rational policy development and to direct future
research and discussion among stakeholders.
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In the United States, the uptake of blood sparing technolo-
gies for surgery has led to a slight reduction in blood use
in recent years (2). However, the utilization of these tech-
nologies is currently low in the United Kingdom, with only
We thank Professor Burnett, Cardiff University and University Hospital of
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study was funded by the National Blood Service for England.
19 percent of hospitals using acute normovolemic hemod-
ilution, 37 percent using cell salvage, and 51 percent us-
ing predeposit autologous donation (6). Even these figures
are deceptively high, as only 6 percent of those hospi-
tals undertaking predeposit autologous donation used more
than 20 units, 4 percent undertaking acute normovolemic
hemodilution used more than 20 units, and 8 percent of those
using cell salvage transfused more than 100 units.
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Figure 1. Structure of the model. PPS, Preparing patients for surgery; PAD, Pre-operative autologous donation; ICS, Intra-
operative cell salvage; PoCS, Post-operative cell salvage; RBCs, Red blood cells.
Interest in the potential role of blood sparing technolo-
gies in the United Kingdom has increased recently due to
the increasing cost of pursuing “zero risk” transfusion; a
unit of blood costs around £100. Also, there are concerns
that, if a test for variant Creutzfeldt–Jakob disease is devel-
oped, donors will stop giving blood as a positive test would
be distressing and may preclude them from life insurance
and mortgage applications (8). Consequently, a contingency
planning exercise was undertaken to assess how the United
Kingdom National Health Service (NHS) could respond to
a severe, prolonged shortage of blood (7). This work was
undertaken in support of the National Blood Service (NBS)
contingency planning exercise.
A recently published systematic review was used in the
choice of the most promising interventions to be considered
(10). The interventions chosen were as follows:
 Preparing patients for surgery (PPS) clinics. Such clinics would
provide a much more rigorous assessment of patients together
with presurgery treatments (e.g., iron supplementation).
 Preoperative autologous donation (PAD). This process involves
the patient donating blood on three occasions in the month before
surgery, thus reducing the need for allogeneic blood.
 Intraoperative cell salvage (ICS). This process involves blood lost
during surgery being “recycled” and filtered for use again in the
patient.
 Post-operative cell salvage (PoCS). This process is applied in
knee replacement patients, and involves blood being collected
postoperatively from around the site of the operation, and being
“recycled” and filtered for use again in the patient.
The aim of the study was to support the policy-making pro-
cess, and in particular, produce national estimates of the
following: scale of potential implementation, costs of im-
plementing the various interventions, reduction in blood use,
and reduced length of stay associated with reductions in in-
fections. Other impacts, such as reductions in the number of
canceled operations, were ruled out of the analysis.
METHODS
A model was constructed to describe health service activity,
the interventions, and their effects. A schematic representa-
tion of the model is shown in Figure 1.
Identification of High Blood-Loss
Operations
To generate cost estimates, a list of operations that would
be suitable for the target interventions was required. The
source of the list that was agreed upon was the Maximum
Blood Ordering Schedule (MBOS) for North Glasgow Uni-
versity Hospitals NHS Trust (www.ngt.org.uk/transfusion/
appendix7/htm). It was decided to focus on five specialties
described in the MBOS: General surgery, Vascular surgery,
Orthopedics, Cardiothoracic surgery, and Obstetrics and Gy-
necology. Transplant surgery was added to this, as it was
considered an important recipient of these technologies. The
operations were classified into four-digit OPCS codes by the
NHS Information Authority and generated over 500 opera-
tion codes.
Identification of Health Service Activity
Once the operation codes for the target operations were
known, annual activity figures for 2000–2001 were taken
from the United Kingdom Hospital Episodes Statistics. For
the purposes of this study, we needed:
 Number of operations by operation code.
 Number of elective and emergency operations by operation code.
This distinction is required as some of the interventions can only
be used for elective operations.
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 Average length of stay by operation code. This is required to
assess potential reductions in length of stay associated with the
interventions.
Identification of Current Blood Use
for Target Operations
A data set covering 8 years of transfusions at a large teaching
hospital (Cardiff and Vale NHS Trust, Cardiff) was identi-
fied, and a data request was granted. The mean blood use
for each operation as described by its OPCS code was calcu-
lated. Mean blood use is defined as total blood use over the
entire patient stay and includes episodes where no blood was
used.
Identification of Resources Required to
Deliver the Intervention
Data on resource use was gathered using a modified Delphi
approach with fifteen experts on autologous transfusion tech-
nologies, by means of postal survey. This method took the
following format:
 Health-care professionals involved in the NBS process would be
asked for their opinions on the costs of implementation of the
technologies and the likely impact on blood use, length of stay,
and canceled operations. The basis of their estimates would also
be elicited (e.g., literature, personal experience, opinion).
 These data would be processed and the results sent back to mem-
bers showing the responses of the group with the reasons for
divergent opinion. Respondents would then be asked to modify
their estimates in light of these data and justify their position.
 This process would be repeated until no further movement in the
position of members was achieved.
A questionnaire was constructed and piloted using local Clin-
ical Hematologists. The revised questionnaire was then sent
out to the health-care professionals involved in the NBS pro-
cess. A total of five responses were received (33 percent
response rate), together with a complete questionnaire from
a pilot survey. Due to the late arrival of most of the question-
naires, the iteration of responses using the modified Delphi
approach was not possible.
Consequently, few data were available to generate unit
costs for the four interventions; therefore, it was decided to
use simple unit costs taken from existing studies or estimated
using known cost of consumables or the cost of the necessary
hospital visits. The unit costs used were as follows:
 Preoperative assessment clinics =£ 74. This value is based on the
average national cost of a “generic” outpatient attendance, taken
from hospital financial returns.
 Preoperative autologous transfusion =£ 222. This value is based
on three generic outpatient attendances.
Table 1. Model Parameters Taken from Expert Opinion
Blood reduction Patients eligible
PPS PAD ICS PoCS PAD PoCS
Orthopedics 10% 30% 20% 30% 40% 50%
Cardiothoracic surgery 20% 10% 30% n/a 30% n/a
Vascular surgery 10% 40% 45% n/a 30% n/a
General surgery 20% 20% 20% n/a 20% n/a
Gynecology 15% n/a n/a n/a n/a n/a
Transplant surgery 5% n/a 45% n/a n/a n/a
PPS, preparing patients for surgery; PAD, preoperative autologous donation;
ICS, intraoperative cell salvage; PoCS, postoperative cell salvage; n/a, not
applicable.
 Intraoperative cell salvage =£ 150. This value is based on the
median cost of disposables used per procedure in the five hospitals
participating in the Trent Cell Salvage Pilot Study (3).
 Postoperative cell salvage =£ 60. This value is based on the
purchase price of a 2-unit bag used to collect blood postoperatively
(Dr. Virge James, personal communication).
Identification of Reductions in Blood Use
and Length of Stay
Satisfactory estimates of blood reductions were not available
from a recent systematic review as its scope was too narrow to
estimate the potential impact of the technologies across hun-
dreds of different operations (10). Consequently, these data
came from the modified Delphi exercise described above.
The six questionnaire responses were used to produce esti-
mates of reduction in blood use for each intervention and the
likely eligibility of patients for PAD and PoCS (Table 1). Not
all interventions can be used for both elective and emergency
operations, and so the following assumptions were made:
 PPS clinics can be used for elective operations only.
 PAD can be used for elective operations only, and within these,
for patients deemed eligible.
 ICS can be used for all operations.
 It is assumed that PoCS is just used for revision of knee prostheses
and total knee arthroplasties only.
Estimation of the reduction in infection rates and length of
stay were taken from a study that had investigated the effects
of allogeneic blood (12). The study investigated 487 patients
undergoing colorectal cancer resection and identified a sta-
tistically significant increase in length of stay of 1.3 percent
associated with each additional unit of red blood cells after
adjusting for 20 confounding factors.
Analysis
The model was constructed in a spreadsheet format and
aimed to produce the following outputs; level of activity
associated with the technologies, gross cost (i.e., excluding
potential savings), reduction in the number of red blood cells
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used, and net cost, including reductions in blood use and
length of stay associated with reduced infection. Costs are
estimated at 2001/2002 prices. Sensitivity analysis was un-
dertaken to assess the robustness of the model estimates to
changes in key variables.
RESULTS
PPS is shown to be potentially the most widely used in-
tervention within the chosen specialties, with over 750,000
operations potentially benefiting from it (Table 2). General
surgery is estimated to show the greatest reduction in blood
use for PPS, although orthopedic surgery is expected to have
the greater reduction in bed days used. Overall, applying
this technology to cardiothoracic surgery appears to be the
most cost-effective, with it saving £ 33 per patient, whereas
gynecology appears to be the most expensive.
PAD is the least cost-effective technology, with an av-
erage cost per patient of £ 133, although this value hides
considerable variation between specialties (Table 2). In par-
ticular, it is potentially cost-saving within vascular surgery.
PAD was not considered appropriate for gynecology or trans-
plant surgery.
ICS is potentially cost saving in four specialties, with
its use in vascular surgery and transplant surgery particu-
larly cost-effective. Its high cost in orthopedics, however,
means that its overall cost per patient is higher than for PPS
(Table 2).
PoCS is only applicable to knee replacement surgery;
therefore, the scale of implementation is relatively small
at just 52,000 operations. However, it is estimated to save
23,264 units of red blood cells and 2,898 bed days, with a
net cost of £ 1 per patient.
Overall, the analysis shows that the technologies could
be applied to around 1.6 million operations, which in turn,
would reduce the number of units of red blood cells used by
783,000 (Table 2). This strategy would require around£ 191
million of funding, although £ 100 million would be gener-
ated in savings associated with reductions in blood use and
bed days. Vascular surgery, transplant surgery, and cardio-
thoracic surgery appear to be the specialties that will benefit
most from the technologies.
The results of the sensitivity analysis show that blood
reductions need to be lowest in cardiovascular surgery and
transplant surgery in order for the technologies to be cost
neutral. In contrast, unrealistic reductions in blood use of
over 70 percent are required for PAD to become cost neutral
(Figure 2).
DISCUSSION
Very little is known about the potential costs and effects of
implementing blood sparing technologies in the United King-
dom. This study provides the first estimates of the costs and
effects of the large scale introduction of these technologies T
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Figure 2. Reductions in blood use required for each tech-
nology to become cost neutral. PPS, preparing patients for
surgery; PAD, preoperative autologous donation; ICS, intra-
operative cell salvage; PoCS, postoperative cell salvage.
into the NHS. The results show the potential for considerable
reductions in blood use. The greatest reductions are antici-
pated to be through the use of ICS (410,000 units per annum)
and PPS (246,000 units per annum).
The estimate of total reductions in blood use across all
technologies is 783,000 units, and this estimate is associated
with a predicted reduction in the number of bed days of
93,000. However, these figures are likely to be overestimates
as they do not take into account interactions between the
technologies being used on the same patients.
Several simplifications were used in the production of
these estimates and should be addressed in future research.
These simplifications are as follows:
 Limited number of specialties. Other specialties are candidates
for the limited use of these technologies.
 Limited number of interventions. Other techniques that may re-
duce the need for allogeneic blood are available, such as hemodi-
lution and patient warming, but have not been considered.
 Limited consultation on the operations suited to each technology.
The list of operations was based on practice at a single hospital.
 Use of blood use data from a single hospital. Blood usage is known
to vary dramatically between hospitals; therefore, we do not know
whether our data reflect the pattern of blood use throughout Eng-
land or beyond the United Kingdom (4;5;9;11).
 Simple cost data were used for each intervention and reductions
in length of stay.
 Estimates of the reduction in hospital stay based on a single study.
 Blood reduction based on professional opinion. Clearly, this is a
severe limitation; however, provisional estimates from the Trent
Cell Salvage study show that they are reasonable and perhaps even
conservative (3).
 Reduced rate of canceled operations and improved discharge re-
sulting in less bed blocking have been ignored. These are two po-
tential operational improvements that may be generated by PPS.
 Other clinical benefits of the interventions have not been factored
into the analysis. Once again, PPS may generate other benefits
such as screening and treating comorbidities, which have not been
included in this study.
Problems with data availability were compounded by the
failure of the modified Delphi exercise to generate sufficient
data to estimate accurately the costs of the various technolo-
gies and their impacts on the health service. This experience
points to the problems in eliciting complex, quantitative data
through postal surveys even from a well-motivated group of
experts involved in the decision-making process.
The interpretation of the “cost savings” needs to be un-
dertaken carefully, as many of them will not be realized.
Reductions in length of stay will not generate savings, as
the free beds will be filled immediately with other patients.
The “savings” associated with reduced length of stay are best
interpreted as improvements in efficiency, or savings that are
immediately re-invested in the provision of hospital care.
Some consideration also needs to be given to the imple-
mentation of the interventions. Some will have consequences
for training and the organization of the health service more
generally. The most important issue, however, is considered
to be the capacity of hospitals to provide the additional PPS
clinics and PAD sessions. Table 2 shows that around 752,000
elective operations could be eligible for PPS in the six spe-
cialties examined, which equates to around 17,000 staffed
outpatient clinics (assuming 15 patients can be seen in a
3-hour session). Likewise, our analysis shows that 152,000
operations could be eligible for PAD (Table 2) in the six
specialties examined, which equate to around 460,000 donor
sessions (assuming three sessions per operation).
The model produced was not aimed at producing detailed
estimates of cost-effectiveness or cost per quality-adjusted
life years. Such a model would need to be more detailed
and would necessarily be more focused on a smaller set of
operations. The aim of this model was quite different; it
was to support the policy-making process by estimating the
potential scale of implementation and the magnitude of re-
duction in red blood cells. Such an approach requires a much
broader view of all operations that will potentially benefit
from the technologies, while requiring a shallower, or less
detailed, analysis of their precise outcomes. This distinction
is absolutely central to assessing the value of this modeling
approach, and we consider it to be “fit for purpose.”
Finally, the figures produced in this study should be con-
sidered as preliminary estimates. Improvements to the esti-
mates can be made incrementally, as more reliable figures are
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produced and would ideally be guided by a value of informa-
tion analysis (1). Despite the drawbacks in the methods used
in the study, the model forms a basis for amalgamating the
data necessary to make informed decisions. It also shows the
scale of the issue, the importance of gathering better data,
and the form that data must take. Such preliminary modeling
exercises are essential for rational policy development and
direct future research and discussion among stakeholders.
Policy Implications
The widespread adoption of the four most promising autolo-
gous blood interventions can significantly reduce the NHS’s
dependence on blood donations; however, this study shows
that it will cost around £ 191 million pounds to implement
in England. Cost offsets in the form of reduced blood use
and lower lengths of stay produces a net cost of around
half this level. Targeting each technology at those specialties
where they are most cost-effective will help reduce the costs
of implementation and will allow time for further research
to produce more accurate estimates of cost-effectiveness. As
well as the traditional form of economic evaluation that looks
at one intervention in one patient population, policy-based
analyses of the kind described here are essential.
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